Abstract:Observing the safety and effectiveness of CT-guide Ad-P53 intratumoral injection to treat patient with recurrent and metastatic gynecologic cancer who underwent local radiation therapy and veinal chemotherapy without other treatment. From October 2012 to December 2015, the Gynecological Radiation Oncology Division, of the First Affiliated Hospital of Xi’an Jiaotong University treated 122 patients with recurrent and metastatic pelvic tumor, of which 47 received local radiation therapy and veinal chemotherapy before having CT-guide Ad-P53 therapy with local multi-point injection into tumor. In each injection, one (1012VP, viral particles) to four medicines was used and diluted to 4-16ml with normal saline; administrated once per week, for 1-6 times altogether. Forty-seven patients received treatment 91 times in total, with dosage of 2±1 pieces on average. The treatment was performed with no radiation therapy and chemotherapy, and considered to end when the tumor regressed or the patient could not tolerate other treatment. Therapeutic evaluation: (1) objective therapeutic evaluation: The efficacy was evaluated one month after treatment according to WHO (Response Evaluation Criteria in Solid Tumors), in combination with the maximum sectional area of the tumor measured through pelvis MRI scan and the regression rate (%) obtained. The safety of implant needle by the CT scan was also observed. (2) Subjective therapeutic evaluation: It was based on the extent of pain relief and vaginal discharge of the patient. 47 patients were follow-up to 27 months and median follow-up time of 11 months by February 2016. Their generation material listed Table 1. No patient had blood vessels, colorectal, bladder and ureter injury resulting from injection medicines by CT-guide. Forty patients (85.1%) had high fever (≥38.5°C) transitorily. Therapeutic evaluation both subjective and objective was made one month after treatment. The results showed that pain and vaginal discharge achieved notable remission of 41 patients (87.2%) and 22 patients (22/27, 81.5%), respectively. 37 patients (78.7%) had appetite and sleeping improved. The objective clinical benefit ratio (CR+PR+SD> one month) of 80.9% (38/47), see Table 2. The median survival time of 11.6 months; 40 ( 85.1%) patients experienced worsen conditions with median progression-free survival of five months. 4 patients whose appetite and sleeping quality were improved after treatment received palliative chemotherapy again. 22 patients (46.8%) died. CT-guide Ad-P53 local injection therapy helps recurrent and metastatic gynecological patients to have effective pain relief, improve quality of life, and showed high safety level. The use of virus vector comes with certain side effect such high fever while the disease remission was shorter. Hence further clinical study and vital fundamental researches are needed on how to conduct gene therapy in a safe and effective way.

Clinical Observation of endoscopy-guided injection of rAd-p53 plus regional artery infusion chemotherapy on advanced gastric carcinoma

In Vitro Effect of Recombinant Human Adenovirus p53 Combined with Epirubicin on Human Gastric Cancer Cells

Combination of Recombinant Adenovirus-P53 with Radiochemotherapy in Unresectable Pancreatic Carcinoma

Safety and Primary Efficacy of Recombinant Human Adenovirus-P53 Injection on Advanced Solid Tumor

Intra-Arterial Infusion Of Recombinant Adenoviral Human P53 Gene Combined Chemotherapy For Advanced Oral Cancer: A Phase Ii Double-Blind Randomized Clinical Trial.

Clinical Observation of the Effect of Recombinant Adenovirus-p53 plus Radio-thermotherapy on Soft Tissue Sarcoma

The Curative Effects and Side Effects of Recombinant Human Adenovirus P53 on Transplanted Gastric Cancer Cells in Nude Mice

Synergistic Gastric Cancer Inhibition by Chemogenetherapy with Recombinant Human Adenovirus P53 and Epirubicin: an in Vitro and in Vivo Study.

Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial

Effects of Recombinant Adenovirus-p53 Combined with Oxaliplatin on Growth Inhibition of Human Gastric Cancer Cell Line SGC-7901

Advanced Malignant Pleural or Peritoneal Effusion in Patients Treated with Recombinant Adenovirus P53 Injection Plus Cisplatin

Effect and Safety of Recombinant Adenovirus-p53 Transfer Combined with Radiotherapy on Long-Term Survival of Locally Advanced Cervical Cancer.

Clinical efficacy and safety of recombinant adenovirus-p53 combined with concurrent radiotherapy and hyperthermia in treatment of advanced soft tissue sarcoma:a study of 76 patients

Application Of Ct-Guided Ad-P53 Intratumoral Injection For Recurrent And Metastatic Gynecologic Cancer Patients Who Received Chemoradiation Therapy

Clinical Effectiveness of Recombinant Adenovirus-P53 Combined with Radiotherapy in Advanced Soft Tissue Sarcoma: A Report of 37 Cases

Effect of Adenovirus-Mediated P53 Gene Transfer on Apoptosis and Radiosensitivity of Human Gastric Carcinoma Cell Lines

Effect of Recombinant Adenovirus-P53 Combined with Radiotherapy on Long-Term Prognosis of Advanced Nasopharyngeal Carcinoma

Clinical observation of intra-cavity rAd-p53 infusion in 34 patients with malignant pleuroperitoneal effusion

47. A Combination Therapy of Selective Intraarterial Gendicine Infusion with Chemotherapy for Locally Advanced Head and Neck Carcinoma

Regional intra-arterial chemotherapy combined with intra-abdominal hyperthermia for treating advanced gastric cancer

Efficacy of Neoadjuvant Regional Arterial Chemotherapy for Patients with Advanced Gastric Cancer